Evaluation of DLL3-Targeted PETCT Imaging for Detecting Tumors in Adults with Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating the diagnostic value of DLL3-targeted PETCT imaging in adults with suspected or confirmed small cell lung cancer SCLC. This study compares DLL3-targeted PETCT with conventional imaging methods such as CT, MRI, and 18F-FDG PETCT. The goal is to assess the ability of DLL3-targeted PETCT to detect tumor lesions and visualize tumor DLL3 expression, providing a potentially noninvasive way to detect tumors in SCLC patients. Participants receive a single intravenous injection of a DLL3-targeted probe followed by PETCT imaging within a specified time. This is done contemporaneously with conventional imaging methods for initial assessment or detection of metastases or recurrence. The study quantifies tumor uptake using the maximum standardized uptake value SUVmax and records the number of tumor lesions detected by both DLL3-targeted PETCT and conventional imaging for comparison. During the study, participants undergo imaging assessments and laboratory tests including immunohistochemistry to correlate tumor DLL3 expression with imaging results. Researchers monitor vital signs after tracer administration and measure radiation absorbed dose over one year. The study evaluates lesion detection rates and diagnostic accuracy. Participants must be able to comply with study procedures and provide informed consent. The study duration includes immediate imaging procedures and follow-up assessments for radiation exposure and safety.

DLL3-Targeted PET/CT in Small Cell Lung Cancer